Core Viewpoint - The company's performance in the first half of 2025 met expectations, with potential for acceleration in the second half, maintaining a buy rating [1] Financial Performance - In H1 2025, the company achieved revenue of 694 million yuan, a year-on-year increase of 5.6%, and a net profit attributable to shareholders of 161 million yuan, up 15.3% [1] - The EPS forecast for 2025-2027 has been slightly adjusted to 0.30, 0.36, and 0.44 yuan respectively, down from 0.31, 0.39, and 0.48 yuan [1] Domestic and International Business Development - The company has made breakthroughs in domestic business, with a 6.0% year-on-year increase in overall domestic revenue to 566 million yuan in H1 2025 [2] - The company has expanded its overseas business, with H1 2025 overseas revenue growing by 4.0% to 128 million yuan, and new registrations in four countries [2] Technological Advancements - The company continues to invest in new technology research and development, with over 1,700 clinical surgeries completed using smart auxiliary devices by the end of June 2025 [3] - The K3 smart surgical robot, fully developed in-house, was approved for market in May 2025 and has already achieved commercialization by the end of August [3]
爱康医疗(1789.HK)2025半年度业绩点评：业绩符合预期 下半年有望提速